Literature DB >> 25277141

Neurophysiologic and antipsychotic profiles of TASP0433864, a novel positive allosteric modulator of metabotropic glutamate 2 receptor.

Tetsuaki Hiyoshi1, Toshiyuki Marumo2, Hirohiko Hikichi2, Yasumitsu Tomishima2, Hiroki Urabe2, Tomoko Tamita2, Izumi Iida2, Akito Yasuhara2, Jun-ichi Karasawa2, Shigeyuki Chaki2.   

Abstract

Excess glutamatergic neurotransmission has been implicated in the pathophysiology of schizophrenia, and the activation of metabotropic glutamate 2 (mGlu2) receptor may exert antipsychotic effects by normalizing glutamate transmission. In the present study, we investigated the neurophysiologic and antipsychotic profiles of TASP0433864 [(2S)-2-[(4-tert-butylphenoxy)methyl]-5-methyl-2,3-dihydroimidazo[2,1-b][1,3]oxazole-6-carboxamide], a newly synthesized positive allosteric modulator (PAM) of mGlu2 receptor. TASP0433864 exhibited PAM activity at human and rat mGlu2 receptors with EC50 values of 199 and 206 nM, respectively, without exerting agonist activity at rat mGlu2 receptor. TASP0433864 produced a leftward and upward shift in the concentration-response curve of glutamate-increased guanosine 5'-O-(3-[(35)S]thio)triphosphate binding to mGlu2 receptor. In contrast, TASP0433864 had negligible activities for other mGlu receptors, including mGlu3 receptor, and did not have any affinity for other receptors or transporters. In hippocampal slices, TASP0433864 potentiated an inhibitory effect of DCG-IV [(2S,2'R,3'R)-2-(2',3'-dicarboxylcyclopropyl)glycine], a mGlu2/3 receptor agonist, on the field excitatory postsynaptic potentials in the dentate gyrus, indicating that TASP0433864 potentiates the mGlu2 receptor-mediated presynaptic inhibition of glutamate release. Moreover, TASP0433864 inhibited both MK-801 [(5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate]- and ketamine-increased cortical γ band oscillation in the rat cortical electroencephalogram, which have been considered to reflect the excess activation of cortical pyramidal neurons. The inhibitory effect of TASP0433864 on cortical activation was also observed in the mouse 2-deoxy-glucose uptake study. In a behavioral study, TASP0433864 significantly inhibited both ketamine- and methamphetamine-increased locomotor activities in mice and rats, respectively. Collectively, these findings indicate that TASP0433864 is a selective mGlu2 receptor PAM with antipsychotic activity, and the attenuation of excess glutamatergic neurotransmission may be involved in the action of TASP0433864.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25277141     DOI: 10.1124/jpet.114.218651

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

Review 1.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

2.  Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI.

Authors:  Joseph E Pero; Michael A Rossi; Michael J Kelly; Hannah D G F Lehman; Mark E Layton; Robert M Garbaccio; Julie A O'Brien; Brian C Magliaro; Jason M Uslaner; Sarah L Huszar; Kerry L Fillgrove; Cuyue Tang; Yuhsin Kuo; Leo A Joyce; Edward C Sherer; Marlene A Jacobson
Journal:  ACS Med Chem Lett       Date:  2016-01-10       Impact factor: 4.345

3.  (2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions.

Authors:  Panos Zanos; Jaclyn N Highland; Brent W Stewart; Polymnia Georgiou; Carleigh E Jenne; Jacqueline Lovett; Patrick J Morris; Craig J Thomas; Ruin Moaddel; Carlos A Zarate; Todd D Gould
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-13       Impact factor: 11.205

Review 4.  Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia.

Authors:  Shalini Dogra; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2022-03-03       Impact factor: 4.054

Review 5.  Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs.

Authors:  Carolina Muguruza; J Javier Meana; Luis F Callado
Journal:  Front Pharmacol       Date:  2016-05-20       Impact factor: 5.810

6.  The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia.

Authors:  Guy Griebel; Philippe Pichat; Denis Boulay; Vanessa Naimoli; Lisa Potestio; Robert Featherstone; Sukhveen Sahni; Henry Defex; Christophe Desvignes; Franck Slowinski; Xavier Vigé; Olivier E Bergis; Rosy Sher; Raymond Kosley; Sathapana Kongsamut; Mark D Black; Geoffrey B Varty
Journal:  Sci Rep       Date:  2016-10-13       Impact factor: 4.379

Review 7.  Presynaptic G Protein-Coupled Receptors: Gatekeepers of Addiction?

Authors:  Kari A Johnson; David M Lovinger
Journal:  Front Cell Neurosci       Date:  2016-11-11       Impact factor: 5.505

8.  Control of impulsivity by Gi-protein signalling in layer-5 pyramidal neurons of the anterior cingulate cortex.

Authors:  Bastiaan van der Veen; Sampath K T Kapanaiah; Kasyoka Kilonzo; Peter Steele-Perkins; Martin M Jendryka; Stefanie Schulz; Bosiljka Tasic; Zizhen Yao; Hongkui Zeng; Thomas Akam; Janet R Nicholson; Birgit Liss; Wiebke Nissen; Anton Pekcec; Dennis Kätzel
Journal:  Commun Biol       Date:  2021-06-02

Review 9.  The cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disorders.

Authors:  Sonia Mediouni; Maria Cecilia Garibaldi Marcondes; Courtney Miller; Jay P McLaughlin; Susana T Valente
Journal:  Front Microbiol       Date:  2015-10-23       Impact factor: 5.640

10.  Modulation of mGlu2 Receptors, but Not PDE10A Inhibition Normalizes Pharmacologically-Induced Deviance in Auditory Evoked Potentials and Oscillations in Conscious Rats.

Authors:  Abdallah Ahnaou; Ria Biermans; Wilhelmus H Drinkenburg
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.